A new CRISPR-engineered cancer model to test therapeutics

October 5, 2017, Broad Institute of MIT and Harvard
Credit: CC0 Public Domain

One major challenge in cancer research is developing robust pre-clinical models for new therapies, ones that will accurately reflect a human response to a novel compound. All too often, a potential treatment that initially looked promising in cells or animal models will not have the same effects in a human cancer patient.

Given the enormous costs of , researchers need pre-clinical models that accurately reflect human disease genetics and reliably predict which drugs have the most potential to succeed in patients. In Cell Stem Cell this week, a team led by Zuzana Tothova, a postdoctoral scholar at the Broad Institute of MIT and Harvard and instructor in medicine at Dana-Farber Cancer Institute (DFCI), and Broad institute member Ben Ebert, also a professor of medicine at Harvard Medical School and chair of medical oncology at DFCI, describe a new approach that has the potential to make this leap.

Using multiplex CRISPR-Cas9 editing of human hematopoietic, or blood-forming, stem followed by transplantation in mice, the team designed customized mouse models for the progression of leukemia. In a number of different experiments, the animal models successfully reflected human responses to a therapeutic agent commonly used to treat blood cancers. "With our models, we can really test—in a very controlled fashion, in the right setting, and using the right cells—the genetic predictors of response to specific agents," said Tothova.

Learning from human genetics

The research team started by examining large-scale sequencing data from Ebert's lab and The Cancer Genome Atlas to determine which combinations of mutations occur most commonly in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), blood cancers in which the bone marrow fails to produce healthy blood cells. The researchers landed on nine genes that are recurrently mutated in MDS and AML.

"We use human genetics to teach us which combinations of mutations lead to ," explained Ebert. "If we have sequencing data from enough tumors, we can identify the genes that are mutated recurrently and which combinations of mutations co-occur more commonly than expected by chance."

Currently, many cancer models (such as cell lines) do not reflect the cancer genetics that a particular investigator would like to study, which often leaves both researchers and patients at a disadvantage. One strategy is to transplant an actual human cancer sample into a mouse, but the cancer tissue often doesn't engraft well, and researchers are only able to test against the specific combination of mutations accumulated in a given cancer sample in the first place.

To study these specific MDS-driving mutations in combination, the team developed a pipeline to insert them into new lab models.

"Say we're trying to develop a new drug against a particular combination of mutations, which we know about through the cancer sequencing efforts," said Tothova. "You might not have any sample available to study with that particular combination of mutations. We wanted to be able to engineer the right lesions in human cells, let them expand in mice, and generate an accurate genetic of disease for testing new therapies. This has been a longstanding goal for cancer researchers, and for the pharmaceutical industry, for a very long time."

Customizing cancer mutations with CRISPR

To create models with the right mutations, Tothova and her team established a customizable system to introduce the cancer-driving mutations into human , where MDS and AML originate. The researchers already had extensive experience working with hematopoietic stem cells and progenitor cells, largely from umbilical cord blood or adult bone marrow, and in 2014, they published a Nature Biotechnology paper in which they described using the CRISPR-Cas9 system to create similar models of mouse cancers. This time, the team was aiming to model MDS in human cells, a much more challenging goal.

The researchers took primary cells from healthy donors and used CRISPR-Cas9 to engineer them with a number of different mutation combinations, rather than a single alteration, in order to reflect the complexity of tumor mutations seen in patients. The combinations of mutations that the cells tolerated—those that successfully altered the genes without killing the cells—and that led to expansion over time were also the ones seen in human tumor samples.

"Nobody so far has done this kind of multiplex CRISPR engineering in the actual hematopoietic stem cell compartment, adding specific mutations in combination to generate disease models," said Tothova.

From there, the team injected the stem cells into the mice's circulatory systems, where a portion incorporated themselves into the . The team monitored their progression, extracting and sequencing the five months later to determine which engineered cells successfully propagated and which mutations became the most common over time in these pre-malignant and early malignant states.

Testing therapeutic agents

The mainstay of treatment for MDS patients are hypomethylating agents called azacitidine and decitabine. Based on previous studies, the team identified specific genetic mutations that could be used to predict cancer cells' response to these compounds in humans. (For example, mutations in a gene called TET2 predict treatment success for MDS patients, while mutations in the ASXL1 gene predict resistance in the tumors.)

When the researchers treated the mice with azacitidine, they found that the response in the engineered cells matched what was expected from the human data: TET2-mutated cells responded to the drug, while ASXL1-mutated cells were resistant to the therapy. The team also discovered that mutations in a cohesin gene, SMC3, increased sensitivity to the drug—data that could be important to clinicians and patients whose tumors share those mutations.

"We are able to recapitulate findings previously seen in human clinical trials, which makes us feel more confident in the power of these models," said Tothova. "The data that comes from patients reflects the most important experiment we are trying to understand." She is currently working with clinical collaborators at DFCI to extend some of these findings into clinical trials.

The team believes their approach to create this type of leukemia progression model for therapeutic testing can be applied to other types of cancer as well, as long as sequencing data is available to choose appropriate and can be acquired from the desired tissue. "People in the field are hungry for these kinds of models," said Ebert. "We are modeling the disease in the right cellular context with a genetic complexity that reflects what we see in patients. This hasn't been done before, and it could become a really beneficial tool."

Explore further: From thousands of suspects, researchers ferret out cancer-causing genes

Related Stories

From thousands of suspects, researchers ferret out cancer-causing genes

August 14, 2017
A Yale-led team of researchers has identified specific gene combinations that can cause deadly brain cancer glioblastoma, using new technology that can also pinpoint triggers of other types cancers, they report Aug. 14 in ...

'Fusion genes' drive formation and growth of colorectal cancer

July 12, 2017
Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

New model could speed up colon cancer research

May 1, 2017
Using the gene-editing system known as CRISPR, MIT researchers have shown in mice that they can generate colon tumors that very closely resemble human tumors. This advance should help scientists learn more about how the disease ...

Studying a catalyst for blood cancers

April 25, 2017
Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Aging-related mutations in blood cells represent major new risk factor for cardiovascular disease

June 22, 2017
Scientists at the Broad Institute of MIT and Harvard have found that a set of genetic mutations in blood cells that arises during aging may be a major new risk factor for cardiovascular disease. In contrast to inherited genetic ...

CRISPR/Cas9 used for rapid functional study of cancer-causing genes

October 26, 2015
In a novel use of the CRISPR/Cas9 system, which can be deployed to switch genes off, researchers from Germany, the UK and Spain have developed a multiplexed screening approach to study and model cancer development in mice. ...

Recommended for you

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

Highly mutated protein in skin cancer plays central role in skin cell renewal

February 20, 2018
Approximately once a month, our skin completely renews itself. If this highly coordinated process goes awry, it can lead to a variety of skin diseases, ranging from skin cancer to psoriasis. Cells lining such organs as skin ...

Study of smoking and genetics illuminates complexities of blood pressure

February 15, 2018
Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of ...

New mutation linked to ovarian cancer can be passed down through dad

February 15, 2018
A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.